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Neuroblastoma is an extra-cranial solid cancer in children. MYCN gene ampliﬁcation is a prognostic
indicator of poor outcome in neuroblastoma. Recent studies have shown that the multiple steps
involved in cell migration are dependent on the availability of intracellular calcium (Ca2+). Although
signiﬁcant advances have been made in understanding the role of Ca2+ during migration, little has
been achieved towards understanding its impact on the progression of diseases such as cancer.
Interestingly, previous studies showed that cancer cell migration is regulated by TRPM7, a cal-
cium-permeable ion channel. The objective of the current study was to elucidate the mechanism
by which MycN promotes NB cell migration and the mechanism regulating TRPM7 expression.
The results showed that MycN increased TRPM7 expression, induced TRPM7 channel activity,
increased intracellular Ca2+ signaling, and promoted cell migration in NB cells. The results also
showed that inhibition or down-regulation of ornithine decarboxylase (ODC) inhibited TRPM7
expression, a process that was reversed by spermidine. Overall, this study provides evidence that
MycN promotes TRPM7 expression and cell migration through a mechanism that involves ODC syn-
thesis of polyamines.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Neuroblastoma (NB) is the most common extra-cranial solid
tumor that occurs in children [26,32,45]. There is clinical heteroge-
neity observed between different NB tumors. The majority of local-
ized NBs can be treated with surgical resection alone, and a subset
of these tumors may regress spontaneously [34]. However, most
patients present with metastatic tumors that have unfavorable
biological features and an aggressive phenotype [7,9,45]. The
long-term survival rate for such patients remains poor compared
to patients with early stages of the disease, despite the availability
of intensive multi-modal therapies. Thus, metastatic forms of the
disease, with poor prognosis, remain a clinical concern [5,8,32].
MYCN gene ampliﬁcation has been shown to drive tumor progres-
sion and is a negative prognostic indicator for NB [7,32]. MycN, the
protein product of the MYCN gene, is a member of the myc family
of transcription factors. MycN contains a C-terminal domain with abasic helix–loop–helix zipper motif (bHLHz), and a N-terminal
transactivation domain that binds to the promoter region of genes
containing E-box sequences, and regulates the expression of those
genes [35,55]. MycN was previously shown to transcriptionally
regulate ornithine decarboxylase (ODC), a rate limiting enzyme
in polyamine biosynthesis [24,28]. MYCN ampliﬁcation and MycN
over-expression has been shown to promote NB cell migration,
invasion and metastasis [21,32,41,56,57]. Interestingly, a recent
study showed that polyamines regulate NB cell migration [27]. Pre-
vious studies have identiﬁed genes that are transcriptionally regu-
lated by Myc, whose protein products play a role in modulating
these processes, including calcium permeable ion channels [18].
However, the roles of MycN and ODC in the regulation of TRPM7
have not yet been examined.
Calcium is a ubiquitous second messenger that plays an impor-
tant role in many fundamental physiological processes, such as
regulating cell cycle, survival, apoptosis, gene expression, cell
migration, invasion and metastasis [1,4,10,16,18,19,30,33,38–
40,43,44,48,50,54]. Recently, calcium-permeable ion channels
(e.g., Orai1, Orai3 and TRPM7) and channel regulators (e.g., Stim1
and Stim2) have been shown to play a role in the malignant pro-
gression of a variety of cancers (e.g., breast cancer, lung cancer,
prostate cancer, glioblastoma, melanoma and cervical cancer).
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family. It is a six transmembrane protein that forms tetramers to
create an outwardly rectifying non-selective cation channel that
is permeable to calcium, magnesium, sodium and trace levels of
zinc. TRPM7 is a channel protein that also contains an intrinsic
ser/thr a-kinase domain at the intracellular C-terminal end
[2,11–13,17,25,42,46]. Recent studies have elucidated a role for
calcium channels and channel regulators in the progression of sev-
eral cancer models. In particular, TRPM7-mediated calcium signal-
ing events have been linked to cell migration, and shown to
regulate actin cytoskeletal rearrangement, focal adhesion turnover,
actin and myosin contraction, protrusion of lamellipodia at the
leading edge of cells and retraction at the trailing edge
[10,19,23,37,48]. However, to date, there have been few studies
that examine the mechanism regulating the expression of TRPM7.
The present study examines whether a relationship exists between
MycN, ODC, TRPM7 and cell migration in NB cells. Gaining a better
understanding of the mechanisms that regulate NB malignant pro-
gression could lead to identiﬁcation of novel targets for the devel-
opment of more efﬁcient treatment strategies for NB, in particular
advanced stage NB withMYCN gene ampliﬁcation. The results from
the present study suggest that MycN promotes TRPM7 expression
and NB migration through a mechanism that involves ODC synthe-
sis of polyamines.
2. Materials and methods
2.1. Cell lines and treatment of cultured cells
All cells were authenticated by the Cell Line Authentication
Testing Services at Genetica DNA Laboratories (USA) using STR
DNA typing to verify each cell line and verify pure cells (no con-
tamination). The human NB cell lines SK-N-SH (ATCC, USA), IMR-
32 (ATCC, USA) h-TERT retinal pigment epithelial cells (provided
by Michael D. Hogarty, PA, USA) and MYCN2 (provided by Jason
Shohet, TX, USA) were maintained in RPMI-1640 (Mediatech, Inc.,
Manassas, VA, USA) containing 10% (v/v) heat-inactivated fetal
bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA, USA).
The MYCN2 cells are SHEP-1 cells with doxycycline inducible
MycN over-expression [49]. The hTERT rat pigment epithelial cells
(RPE-1) were also used. RPE-1 are non-cancerous cells with tamox-
ifen-inducible MycN over-expression. Cells in early log-phase were
seeded and for MYCN2 cells, doxycycline (100 ng/ml) was added
3 h after seeding. For pharmacological inhibition of ODC1, NB cells
were treated with 5 mM a-diﬂuoromethylornithine (DFMO) for
72 h. NB cells were cultured at 37 C, in a humidiﬁed atmosphere
containing 5% CO2.
2.2. Western blot analysis
Cell lysates were prepared in RIPA buffer [20 mM Tris–HCl, pH
7.5, 0.1% (w/v) sodium lauryl sulfate, 0.5% (w/v) sodium deoxycho-
late, 135 mM NaCl, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 2 mM
EDTA], supplemented with Complete protease inhibitor cocktail
(Roche Molecular Biochemicals, Indianapolis, IN, USA), and phos-
phatase inhibitors sodium ﬂuoride (NaF) (20 mM) and sodium van-
adate (Na3VO4) (0.27 mM). Western blot analysis was performed as
previously described [28]. The total protein concentration was
determined using the protein assay dye reagent from Bio-Rad Labo-
ratories (Hercules, CA, USA). Cell lysates in SDS-sample buffer were
boiled for 5 min and equal amounts of total protein analyzed by 10%
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and western
blotting. The antibodies used in this study are: rabbit monoclonal
TRPM7 (at a 1:1000 dilution from Epitomics, Inc. (Burlingame, CA,
USA)), rabbit polyclonal MycN (at a 1:500 dilution), goat polyclonal
ODC (at a 1:500 dilution) and mouse monoclonal GADPH (at a1:1000 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Secondary anti-mouse (at a 1:10,000 dilution) IR-680 or IR-800
(LI-CORBiosciences, Lincoln, NB, USA). Proteinswere detected using
the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln,
NB, USA) and analyzed with Licor Image Studio 2.0 acquisition
and analysis software.
2.3. Reverse transcription polymerase chain reaction
RNA was isolated using TRIzol/chloroform (Invitrogen Life Tech-
nologies, Grand Island, NY, USA). Template cDNA was generated
using GoScript Reverse Transcriptase (Promega, Madison, WI,
USA). PCR reactions were performed using GoTaq DNA Polymerase
(Promega, Madison, WI, USA).
Primer sequences for GADPH were:
 Sense: AAATTGAGCCCGCAGCCTCCC
 Antisense: CTGCAAATGAGCCCCAGCCTTCT
Primer sequences for TRPM7 were:
 Sense: TGGACAGCAGTGGCTGGTTGG
 Antisense: TGGTCGGTAGGGCTGTGCTGT
Primer sequences for Orai3 were:
 Sense: TTGCTCCACTGGGGGTGCCT
 Antisense: ATGGCCACCATGGCGAAGCC
Primer sequences for Stim1 were:
 Sense: GGCCAAGGAGGGGGCTGAGA
 Antisense: GGAGGTTTGGGGGCCACACG
Primer sequences for Stim2 were:
 Sense: TCCCTGCATGTCACTGAGTC
 Antisense: GGGAAGTGTCGTTCCTTTGA
Primer sequences for TRPC1 were:
 Sense: GATGGCGGCCCTGTACCCGA
 Antisense: ACGAAACCTGGAATGCCGGAGG
Primer sequences for KCa3.1 were:
 Sense: GTGCTCGTGGGCGCTCTACC
 Antisense: CCAGAGGCCAAGCGTGAGGC
Primer sequences for p27 were:
 Sense: AGTGCGAGAGAGGCGGTCGT
 Antisense: GAGGCCAGGCTTCTTGGGCG
2.4. Knockdown experiments with siRNA
Cells were transfected with siRNA from Santa Cruz Biotechnol-
ogy, Inc. The TRPM7-speciﬁc siRNA (sc-42662) used in this study
were:
sc-42662A:
 Sense: GAGAUGUGGUUGCUCCUUAtt
 Antisense: UAAGGAGCAACCACAUCUCtt
sc-42662B:
 Sense: CCAUAUUGGGUCAGAUGAAtt
 Antisense: UUCAUCUGACCCAAUAUGGtt
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 Sense: GCAUUAGUUGCCUGUAAGAtt
 Antisense: UCUUACAGGCAACUAAUGCtt
The MycN speciﬁc siRNA (sc-36003) used in this study were:
sc-36003A:
 Sense: CAGCAGCAGUUGCUAAAGATT
 Antisense: UCUUUAGCAACUGCUGCUGTT
sc-36003B:
 Sense: GGAAGUUCAUACCUAAGUATT
 Antisense: UACUUAGGUAUGAACUUCCTT
sc-36003C:
 Sense: CCUGUAUACUUUAGUAUGATT
 Antisense: UCAUACUAAAGUAUACAGGTT
The ODC-speciﬁc siRNA (sc-43982) used in this study were:
sc-43982A:
 Sense: CUUUCACGCUUGCAGUUAAtt
 Antisense: UUAACUGCAAGCGUGAAAGtt
sc-43982B:
 Sense: GUGAUUGGAUGCUCUUUGAtt
 Antisense: UCAAAGAGCAUCCAAUCACtt
sc-43982C:
 Sense: GGAUAUGGGUCACACUUAUtt
 Antisense: AUAAGUGUGACCCAUAUCCtt
Note: all sequences are provided in 50?30 orientation.
The scrambled control siRNA (sc-36869) was from Santa Cruz.
Brieﬂy, siRNA (40–80 pmol) and Lipofectamine 2000 reagent
(10 ll) were diluted, in separate vials, in serum-free RPMI1640.
After 5-min incubation at room temperature, the siRNA and Lipo-
fectamine 2000 were mixed together and incubated at room tem-
perature for an additional 30 min, then added to the cells. The
medium was exchanged with RPMI1640 supplemented with 10%
FBS after overnight incubation. The cells were analyzed at 48 h
post-transfection.
2.5. Transwell migration assay
Migration and invasion assays were performed as outlined in
the manufacturer’s protocol (Trevigen, Gaithersburg, MD, USA).
Brieﬂy, transwell plates were either coated with basement mem-
brane extract (BME) solution and allowed to incubate for 4 h at
37 C in a CO2 incubator, or left uncoated. Serum-starved cells
(5  104 cells) were seeded into the top chamber in medium with-
out FBS, while medium with FBS was present in the bottom cham-
ber. The cells were incubated for 24 h. The media and remaining
cells were aspirated from the top chamber and washed 2 times
with 1 wash buffer. The bottom chamber was aspirated and
washed 2 times with 1 wash buffer. Calcein-AM in cell dissocia-
tion buffer was added to the bottom chamber, and incubated for
1 h. The top chamber was removed and the ﬂuorescence intensity
(calcein-AM labeled cells) was measured at 485 nm excitation
(520 nm emission) using a plate reader.2.6. Immunoﬂuorescent calcium measurements
For immunoﬂuorescence microscopy, cells were grown in 96
well format incubated with Fluo-4-AM (Invitrogen Life Technolo-
gies, Grand Island, NY, USA) at 2 lM for 45 min and washed once
in PBS containing calcium. Epiﬂuorescence measurements were
performed using an Operetta High Content Imaging System (Perk-
inElmer, Santa Clara, CA, USA). Fluorescence intensity was quanti-
ﬁed using Harmony (PerkinElmer, Santa Clara, CA, USA).
2.7. Patch-clamp measurements
Patch-clamp experiments were performed under whole-cell
conﬁguration at 21–25 C using a HEKA EPC10 ampliﬁer. Voltage
ramps of 100 ms duration spanning from 100 to +100 mV were
delivered at a rate of 0.5 Hz from a holding potential of 0 mV.
External solution contained (mM) 140 NaCl, 2.8 KCl, 1 MgCl2, 1
CaCl2, 10 HEPES and 11 mM glucose. The standard internal solution
contained (mM) 140 Cs-Glutamate, 8 NaCl, 10 HEPES and 10 BAP-
TA. 1 mM ATP was added to the internal solution for IMR32 and
SK-N-SH experiments. Currents were normalized to cell size in
pF. Data points for inward and outward current amplitudes were
obtained at 80 and +80 mV respectively. Currents were normal-
ized to the current obtained before development of TRPM7 medi-
ated currents.
2.8. Affymetrix DNA micro-array hybridization and analysis
There are expression proﬁles for 88 NB tumors in the Affyme-
trix ‘‘NB88’’ NB tumor dataset, and 649 NB tumors in the ‘‘Kocak-
649’’ tumor dataset. Both tumor sets have documented genetic
and clinical features. Brieﬂy, total RNA was extracted from frozen
NB tumors which contained >95% NB cells, and labeled cRNA was
hybridized to Affymetrix Human genome U133 Plus 2.0 micro-
array (Affymetrix, Santa Clara, CA, USA) as previously described
[47]. The NB tumor sets were accessed through the Gene Expres-
sion Omnibus (GEO) database at the NCBI website (GEO:
GSE16476, GSE45547). The mRNA levels were determined from
data image ﬁles using MAS5.0 from Affymetrix. Affymetrix
probe-sets were selected using the R2 bio-informatic platform
(http://r2.amc.nl). The Kocak-649 tumor set was analyzed for cor-
relation between MycN and TRPM7, as the tumor set contained
the largest number of non-ampliﬁed and MYCN gene ampliﬁed
NB tumors. The NB88 tumor set was used for Kaplan–Meier
graph to analyze the survival prognosis of patients based on high
or low expression of TRPM7. Further analysis of the NB88 tumor
set was performed in NB tumors to separate alive and not-alive
patient samples. The tumors were separated into one group with
surviving patients (right panel-alive category was highlighted in
green) and those that are not alive (left panel-alive category
was highlighted in red), and further divided into MycN ampliﬁed
tumors and TRPM7 expression. All analyses were performed
using R2, an Affymetrix analysis and visualization platform devel-
oped in the Department of Oncogenomics at the Academic Med-
ical Center at the University of Amsterdam. R2 can be accessed
at: http://r2.amc.nl. Anova, Student’s t-test or Kruskal–Wallis t-
tests were used as appropriate. 2logPearson correlation was used
to assess statistical signiﬁcance of correlation of mRNA
expression.
2.9. Statistical analysis
In those cases where statistical comparisons were made, paired
Student’s t-test was used.
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3.1. TRPM7. expression correlates with MYCN ampliﬁcation and lower
survival probability
To examine whether MycN correlated with TRPM7 mRNA
expression, the Kocak-649 tumor set and the R2 microarray analy-
sis visualization platform were used (http://r2.amc.nl). The mRNA
expression for MycN and TRPM7 was measured with Affymetrix
proﬁling. The MYCN gene ampliﬁed tumors were separated from
the MYCN non-ampliﬁed tumors and the mRNA expression of
TRPM7 were examined. Fig. 1A shows that TRPM7 was expressed
in all tumor samples. However, TRPM7 expression was signiﬁ-
cantly higher in MYCN ampliﬁed tumors, and there is a correlation
between MycN expression and TRPM7 expression (p < 2.3E07).
This suggests that MycN expression promotes TRPM7 expression.
Next, we examined the expression of TRPM7 and its clinical rel-
evance in NB. Using a Kaplan–Meier scan analysis, a correlation
between TRPM7 mRNA expression and NB patient survival was
observed (Fig. 1B). The signiﬁcant p-value was calculated when
NB88 tumor set was divided into 31 tumors with low TRPM7
mRNA expression, and 57 tumors with high expression of TRPM7
mRNA. The survival of patients with low TRPM7 expression
(n = 31) was 80% for up to 216 months, while the survival of
patients with high TRPM7 expression (n = 57) dropped to 50%
(p = 0.02). The NB88 tumor set was further analyzed for TRPM70
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Fig. 1. (A) TRPM7 gene expression is correlated to MycN expression and patient prognos
Illustration of TRPM7 and MycN expression in all 88 NB tumors. There is a direct correla
graph shows the survival prognosis of patients with tumors that are part of the NB88 tum
probability is signiﬁcantly higher in patients with low TRPM7 expression, compared to th
group with surviving patients (right panel-alive category was highlighted in green) and t
divided into MycN ampliﬁed tumors and TRPM7 expression. (For interpretation of the ref
article.)and MYCN expression and patient survival. Fig. 1C shows that 33
NB patients from the NB88 tumor set did not survive. 29 of the
33 patients that did not survive had stage 4 NB (Fig. 1C). 14 out
of the 16 patients withMYCN ampliﬁed NB tumors did not survive,
and had higher TRPM7 expression (Fig. 1C). These data suggest that
TRPM7 expression correlates with MycN expression and decreased
survival of NB patients.
3.2. MycN regulates TRPM7 expression
Previous studies have shown that MycN over-expression and
MYCN gene ampliﬁcation promotes NB cell migration, invasion
and metastasis [41]. In order to identify the channel protein(s)
involved in MycN-induced NB cell migration, semi-quantitative
reverse-transcriptase polymerase chain reaction (RT-PCR) was per-
formed on tetracycline-inducible MycN over-expressing NB cells,
MYCN2 cells. Previous studies have optimized the induction of
MYCN2 cells with doxycycline. Cells grown in culture in media
containing doxycycline for 96 h consistently showed signiﬁcant
increases in MycN expression, and expression of down-stream
MycN targets. Therefore, the same conditions were used in the cur-
rent study. MYCN2 cells cultured in media without doxycycline
were designated as MycN-off and MYCN2 cells cultured in media
with doxycycline were designated as MycN-on. The mRNA expres-
sion of TRPM7 was determined using total RNA extracted from
MycN-on and MycN-off cells, and performing semi-quantitativeAge group 
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is. TRPM7 gene expression correlates with MycN expression in NB tumor set, NB88.
tion between TRPM7 and MycN expression with p < 2.3E07. (B) The Kaplan–Meier
or set. The survival prognosis is based on high or low expression of TRPM7. Survival
ose with high TRPM7 expression (p < 0.02). (C) The tumors were separated into one
hose that are not alive (left panel-alive category was highlighted in red), and further
erences to color in this ﬁgure legend, the reader is referred to the web version of this
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mRNA expression of Orai3, Stim1, TRPC1 and KCa3.1 were higher
in MycN-on compared to MycN-off cells. However, the mRNA
expression of TRPM7 expression in MycN-on cells was consistently
signiﬁcantly higher than that of MycN-off cells (Fig. 2A). Therefore,
in the current study, we focused on investigating the regulation of
TRPM7 in NB. In order to conﬁrm the increase in TRPM7 expression
at the protein level, whole cell lysates fromMycN-on and MycN-off
NB cells were analyzed by western blot. In addition, western blot
analysis was also performed using whole cell lysates from SK-N-
SH and IMR-32 cells, MYCN non-ampliﬁed and MYCN gene ampli-
ﬁed NB cells, respectively. The results showed that TRPM7 protein
expression was signiﬁcantly higher in MycN-on cells compared to
MycN-off cells, and TRPM7 protein expression was signiﬁcantly
higher in IMR-32 cells compared to SK-N-SH cells (Fig. 2B). The
band density in each lane of the western blot was quantiﬁed, and
the level of TRPM7 protein in SK-N-SH, IMR-32, MycN-off, and
MycN-on cells were normalized to GAPDH expression. MycN-on
cells had 4.5 higher TRPM7 expression than MycN-off cells
(Fig. 2C). The TRPM7 expression in IMR-32 cells was 9 higherA 
D  
B
Fig. 2. (A) Semi-quantitative RT-PCR were performed using total RNA extracted MycN-
KCa3.1 expression. P27, GAPDH and water were used as controls. (B) Western blot analysis
MycN-on cells. The membranes were probed for TRPM7 and MycN expression. GAPDH
(Burlingame, CA, USA)), rabbit polyclonal MycN (at a 1:500 dilution), and mouse monocl
Secondary anti-mouse (at a 1:10,000 dilution) IR-680 or IR-800 (LI-COR Biosciences, Linc
as mean ± stdev, n = 3 independent experiments, ⁄p 6 0.05. (D) Western blot analysis wa
transfected (lipofectamine only), IMR-32 cells transfected with scrambled siRNA (Scr
membranes were probed for MycN and Full length TRPM7 expression, and GAPDH w
(Burlingame, CA, USA)), rabbit polyclonal MycN (at a 1:500 dilution), and mouse monocl
Secondary anti-mouse (at a 1:10,000 dilution) IR-680 or IR-800 (LI-COR Biosciences, Li
prepared from non-cancerous hTERT-immortalized retinal pigment epithelial cells (RPE-
RPE-1 cells without tamoxifen induction and therefore, does not express MycN. The p
expression. The PVDF membranes were probed for MycN and TRPM7 expression. GAPD
(Burlingame, CA, USA)), rabbit polyclonal MycN (at a 1:500 dilution), and mouse monocl
Secondary anti-mouse (at a 1:10,000 dilution) IR-680 or IR-800 (LI-COR Biosciences, Linthan SK-N-SH cells (Fig. 2C). The data indicates that there is a cor-
relation between MycN and TRPM7 expression in NB cells.
In order to conﬁrm the regulation of TRPM7 expression by
MycN, MycN speciﬁc and scrambled siRNA were transfected into
IMR-32, NB cells with MYCN gene ampliﬁcation. Whole cell lysates
were prepared from IMR-32 cells transfected with MycN siRNA,
scrambled siRNA, and mock transfected cells (transfection reagent
only). TRPM7 protein expression was analyzed by western blot.
MycN siRNA signiﬁcantly decreased MycN and TRPM7 expression
compared to scrambled siRNA and mock transfected cells
(Fig. 2D). In order to provide further evidence that MycN regulates
TRPM7 expression, MycN was over-expressed in hTERT-immortal-
ized retinal pigment epithelial cells (RPE-1 cells), a non-cancerous
cell line, using a tamoxifen-inducible system. Tamoxifen induced
MycN over-expression in RPE-1 cells, and signiﬁcantly increased
TRPM7 expression in RPE-1 cells, compared to RPE-1 cells without
tamoxifen-induced MycN over-expression (Fig. 2E). These results
show that down- or up-regulation of MycN expression leads to a
corresponding decrease or increase in TRPM7 expression, respec-
tively, providing additional evidence that MycN regulates TRPM7   E
C
off and MycN-on cells, to assess levels of Orai3, STIM1, STIM2, TRPM7, TRPC1, and
was performed on whole cell lysates prepared from SK-N-SH, IMR32, MycN-off and
was used as a loading control. TRPM7 (at a 1:1000 dilution from Epitomics, Inc.
onal GADPH (at a 1:1000 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
oln, NB, USA). (C) The density of the TRPM7 band was quantiﬁed and data expressed
s performed on whole cell lysates from control (CTR) IMR-32 cells that were mock
), and IMR-32 cells transfected with MycN speciﬁc siRNA (KD MycN). The PVDF
as used as a loading control. TRPM7 (at a 1:1000 dilution from Epitomics, Inc.
onal GADPH (at a 1:1000 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
ncoln, NB, USA). (E) Western blot analysis was performed using whole cell lysates
1) with tamoxifen-inducible MycN over-expression. The minus signs () represent
lus signs (+) represent RPE-1 cells treated with tamoxifen to induce MycN over-
H was used as a loading control. TRPM7 (at a 1:1000 dilution from Epitomics, Inc.
onal GADPH (at a 1:1000 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
coln, NB, USA). All the date presented were n = 3–5 independent experiments.
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and TRPM7 expression (shown in Fig. 1A).
3.3. MycN regulation of TRPM7 expression results in a corresponding
increase in TRPM7 channel activity
In order to determine whether MycN-induced TRPM7 expres-
sion leads to a corresponding increase in functional TRPM7 chan-
nels, electrophysiological measurements of TRPM7 channel
activity were recorded using the whole-cell conﬁguration. Charac-
teristically, upon membrane rupture and initiation of current
recordings, TRPM7 currents develop over time. TRPM7 current
density was examined in MycN-on cells and MycN-off cells at
+80 mV (Fig. 3A). TRPM7 mean current densities increased to a
peak current of 7 pA/pF (at 500 s) in MycN-on cells, compared
to 4 pA/pF currents (at 400 s) in MycN-off cells (Fig. 3A). The
current/voltage relationship (IV curve) was characteristic of TRPM7
channels (Fig. 3B), displaying a large outwardly rectifying current,A  
C   
E
Fig. 3. Electrophysiological measurements were recorded, and TRPM7 current densities a
red arrows indicate the current/voltage relationship characteristic of TRPM7 was observe
as mean ± SEM, n = 7–20. (For interpretation of the references to colour in this ﬁgure legand a very small inward current. In addition, TRPM7 mean current
densities developed to a peak current of 15 pA/pF in IMR32 cells,
compared to 4 pA/pF in SK-N-SH cells (Fig. 3C). The IV curves
were also characteristic of TRPM7, and displayed a larger outward
current in IMR32 cells compared to SK-N-SH cells (Fig. 3D). The
data suggest thatMYCN gene ampliﬁcation and MycN over-expres-
sion signiﬁcantly increases TRPM7 channel activity under condi-
tions where physiological MgCl2 (1 mM) was present in the
external solution.
In order to conﬁrm that MycN resulted in an increase in func-
tional TRPM7 channels, and that the increased current was medi-
ated by TRPM7, electrophysiological measurements were
recorded on NB cells perfused with different concentrations of
MgCl2. MgCl2 has been shown to be a potent inhibitor of TRPM7-
mediated currents. Fig. 3E shows that TRPM7 currents developed
in IMR-32 cells to greater extent when external MgCl2 was kept
at 0 mM, and application of 3 mM MgCl2 effectively abolished
TRPM7 currents. Removing the 3 mM MgCl2 restored TRPM715
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972 I. Lange, D.-L.T. Koomoa / FEBS Open Bio 4 (2014) 966–975currents. The IV curves were characteristic of TRPM7, and 3 mM
MgCl2 shows a signiﬁcant decrease in outward current (Fig. 3F).
The data suggests that MycN induces the expression of functional
TRPM7 channels and increases TRPM7-mediated currents.
3.4. TRPM7 regulates NB cell migration
In order to conﬁrm the role of TRPM7 in regulating NB cell
migration, TRPM7 speciﬁc siRNA was used to down-regulate
TRPM7 expression. TRPM7 speciﬁc or scrambled control siRNA
was transfected into MYCN2 cells, or cells were mock transfected
(transfection reagent only). In order to conﬁrm down-regulation
of TRPM7 protein expression, western blot analysis was performed
on whole cell lysates from TRPM7 siRNA and scrambled siRNA
transfected cells, as well as mock transfected control cells.
Fig. 4A shows that TRPM7 expression in MycN-off (Fig. 4A) and
MycN-on (Fig. 4B) cells is decreased by TRPM7 siRNA, compared
to scrambled siRNA and mock transfection control. The band den-
sities in each lane of the blots were quantiﬁed and normalized to
GAPDH. TRPM7 siRNA decreased the protein expression of TRPM7
by 21% and 49% in MycN-off and MycN-on cells, respectively, com-
pared to scrambled control cells (Fig. 4C and D). Next, the effect of
TRPM7 down-regulation on NB cell migration was determined. In
MycN-off and MycN-on cells, TRPM7 siRNA decreased the migra-
tion of NB cells by 36% and 65%, respectively, compared to
scrambled control cells (Fig. 4E and F). The results provide further
evidence that TRPM7 plays a role in regulating NB cell migration.
3.5. Pharmacological inhibition of TRPM7 currents inhibit NB cell
migration
In order to determine the role of TRPM7 in regulating NB cell
migration, NB cells were treated with 100 lM 2-aminoethoxydi-
phenyl borate (2-APB) or left untreated. 2-APB has been shown
to inhibit TRPM7-mediated currents [22]. The TRPM7 channelA 
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After TRPM7 currents developed, IMR-32 cells were perfused with
2-APB. Fig. 5A shows that 2-APB application signiﬁcantly decreased
TRPM7 channel activity. The current voltage relationship was char-
acteristic of TRPM7, and indicates that the current was mediated
by TRPM7 (Fig. 5B). In addition, 2-APB inhibited NB cell migration
by 9.2% and 46.4% in MycN-off and MycN-on cells, respectively
(Fig. 5C). These results suggest that TRPM7 channel activity is crit-
ical for NB cell migration.
3.6. Polyamines regulate TRPM7 expression
Previous studies showed that MycN regulates ODC expression
and activity [20,24,28]. In addition, studies have shown that the
irreversible ODC inhibitor, a-diﬂuoromethylornithine (DFMO), sig-
niﬁcantly depleted intracellular polyamine levels which led to
inhibition of NB cell migration, an effect that was attenuated by
addition of exogenous polyamines in the culture media [27]. How-
ever, the mechanism by which MycN regulates TRPM7 and NB
migration remains unknown. To examine the effect of intracellular
polyamines on TRPM7 expression, ODC was pharmacologically
inhibited by 5 mM DFMO using standard conditions and time-
points to optimize the depletion of intracellular polyamines, as
described in previous literature [24,25,28,53]. Whole cell lysates
from untreated and DFMO-treated cells were analyzed by western
blot for TRPM7 expression. DFMO signiﬁcantly inhibited TRPM7
expression, compared to untreated cells (Fig. 6A). This effect was
reversed by supplementing the culture media with 10 lM spermi-
dine during DFMO treatment (Fig. 6A). PMA was used to stimulate
ODC however TRPM7 expression was not signiﬁcantly altered
under these conditions. The band densities in each lane of the blots
were quantiﬁed and normalized to GAPDH. Fig. 6C shows that
DFMO decreased TRPM7 expression by 27.8% and 65.7% in MycN-
off and MycN-on cells, respectively. To further examine and con-
ﬁrm the role of intracellular polyamines in the regulation of TRPM70
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expression. ODC1-speciﬁc siRNA effectively down-regulated ODC
expression and TRPM7 expression, compared to scrambled siRNA
control (Fig. 6B). The band densities in each lane of the blots were
quantiﬁed and normalized to GAPDH. ODC siRNA decreased ODC
protein expression by 38.4% and 58.7% in MycN-off and MycN-on
cells, respectively (Fig. 6D). ODC siRNA also decreased TRPM7 pro-
tein expression by 49.1% and 65.1% in MycN-off and MycN-on cells,respectively (Fig. 6D). These results show that intracellular poly-
amines regulate TRPM7 expression.
4. Discussion
Neuroblastoma (NB) is an extra-cranial pediatric cancer. Meta-
static forms of the disease, with poor prognosis, remain a clinical
concern [6,7,9,35]. The current study examined the mechanism
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relationship between MycN, ODC, TRPM7 channel, and cell migra-
tion in NB cells with different MYCN status (e.g., non-ampliﬁed
MYCN gene, MYCN gene ampliﬁed and MycN over-expression).
TRPM7 expression has been shown to promote cell proliferation
and metastasis in various cancers [10,16,19,22,36,43,48]. Previous
studies have shown that MycN promotes NB migration and inva-
sion by regulating the expression of genes involved in cell migra-
tion, invasion and metastasis, including integrin proteins, focal
adhesion kinase [3,15,31,51], ODC and TRPM7 [27,29]. The results
from the current study showed that TRPM7 expression correlated
with MycN expression, and Kaplan–Meier survival data showed
that TRPM7 expression correlated with decreased patient survival.
In vitro data demonstrated that TRPM7 mRNA and protein expres-
sion was increased in NB cells withMYCN gene ampliﬁcation (IMR-
32), and MycN-on NB cells, compared to non-ampliﬁed (SK-N-SH)
and MycN-off cells. Next, we showed that MycN speciﬁc siRNA
effectively decreased MycN and TRPM7 expression. Interestingly,
MycN over-expression in RPE-1 cells (a non-cancerous, retinal pig-
ment epithelial cell line) also resulted in an increase in TRPM7
expression. Therefore, the expression of MycN promotes the
expression of TRPM7 in non-cancerous and cancer cell lines. The
data from the current study provide strong evidence that up- or
down-regulation of MycN induces a corresponding increase or
decrease in TRPM7 expression. In addition, electrophysiological
measurements showed increased TRPM7 currents (ITRPM7) in cells
with MYCN gene ampliﬁcation and over-expression of MycN, com-
pared to cells with single copy of theMYCN gene. The current/volt-
age relationship (IV curve) was characteristic of TRPM7 channels
(Fig. 2B), displaying a large outwardly rectifying current, when
positive potentials promotes the transport of mainly monovalent
ions out of the cell, and a very small inward current representing
the transport of divalent cations (e.g., calcium and magnesium)
from the extracellular space into the cells down their concentra-
tion gradients. This speciﬁc IV relationship is only observed with
TRPM7 channels. The IV relationships of other TRP channels
involve a more linear curve at both negative and positive potentials
and/or less outward rectiﬁcation. In addition, the TRPM7 current
was completely abolished by 3 mM MgCl2, which has been estab-
lished as a potent blocker of the TRPM7 channel activity [2]. These
data provide strong evidence that MycN increases TRPM7 expres-
sion and consequently induces an increase in TRPM7 channel
activity. This is the ﬁrst study that shows a relationship between
MycN and TRPM7 expression and channel activity. However, it is
not known whether MycN regulates TRPM7 directly, or through
an indirect mechanism. Review of current literature and data from
Myc target databases revealed that TRPM7 is not a transcriptional
target of MycN. However, it has been shown that ODC is a tran-
scriptional target of MycN in NB cells. A recent study demonstrated
that the irreversible inhibitor of ODC, DFMO, depleted intracellular
polyamine levels and signiﬁcantly inhibited NB cell migration,
effects that were attenuated by supplementing external media
with exogenous polyamines. The results from the study suggests
that polyamines regulate NB cell migration. However, the mecha-
nism by which polyamines regulate NB cell migration remain
unknown. Therefore, the current study investigated whether or
not intracellular polyamines act down-stream of MycN to regulate
TRPM7 expression. Previous studies have established that 5 mM
DFMO effectively decreased ODC activity and depleted intracellu-
lar polyamine levels in NB cells [20,28,53]. The same conditions
were employed in the current study. DFMO and ODC speciﬁc siRNA
effectively decreased TRPM7 protein expression in NB cells. The
results suggest that the mechanism by which MycN regulates
TRPM7 expression involves intracellular polyamines. Polyamines,
at physiological pH, are positively charged, and are able to bind
to DNA, RNA and protein. Consequently, polyamines have beenshown to regulate DNA replication, transcription, translation and
protein function. Due to the fact that MYCN upregulates TRPM7
expression, at both the mRNA and protein level, suggests that the
regulation may occur at the level of transcription. The mechanism
by which MycN promotes NB migration may involve
MycN-induced polyamine synthesis, polyamine-mediated up-reg-
ulation of TRPM7 expression and increased TRPM7 channel activ-
ity. These events appear to play a critical role in regulating NB
cell migration.
TRPM7 is a bi-functional protein that contains an ion channel
fused to an a-kinase domain at the C-terminal end. TRPM7 has
been shown to modulate focal adhesion number, cell–cell adhe-
sion, actomyosin contractility, invadosome formation and direc-
tional cell movement. In the current study, NB cell migration was
inhibited by TRPM7 speciﬁc siRNA providing further evidence that
MycN potentiation of NB cell migration may occur through a
mechanism that involves TRPM7. Previous studies have shown that
cleavage of the TRPM7 kinase domain plays a role in regulating NB
migration. TRPM7 kinase mediates phosphorylation of myosin
IIHA, regulating actomyosin contraction during cell migration
[14,52]. A recent study showed that TRPM7 regulates the forma-
tion of invadosomes and focal adhesions independent of TRPM7-
mediated calcium inﬂux. The current study focused on the regula-
tion of the TRPM7 channel expression by MYCN, events that do not
involve the TRPM7-kinase but are also required for NB cell
migration.
In conclusion, the results from the present study suggests that
MycN transcriptionally regulates ODC expression and increases
polyamine biosynthesis, which leads to increased TRPM7 expres-
sion, increased TRPM7 channel activity, and increased intracellular
calcium, all of which ultimately promotes NB cell migration. This is
the ﬁrst study demonstrating a link between the prognostic factor,
MycN, and NB malignant progression with a calcium channel, in
this case TRPM7. In addition, this study provides evidence that
MycN regulates TRPM7 through a mechanism that involves intra-
cellular polyamines and ODC.
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